CagriSema combines semaglutide with cagrilintide, an amylin analog, showing 20.4% weight loss in recent Phase 3 trials
This structural advantage translates directly into research utility: tesamorelins longer active window allows protocols designed to study sustained GH stimulation, prolonged IGF-1 elevation, and cumulative effects on fat distribution applications where sermorelins rapid clearance would be limiting
A non-peptide structure reduces enzymatic degradation concerns and simplifies stability considerations in research workflows
These newer drugs were really just breaking onto the scene, but boy did we not know how they would shake the game up
You lose some weight with semaglutide alone, but its not a miracle drug
In this guide, well break down how Ozempic works, whether timing affects results, and how to choose a schedule that helps you stay on track